IBISWorld Platform
Answer any industry question in minutes with our entire database at your fingertips.
Brand name pharmaceutical manufacturers in the US are some of the most lucrative in the world. Consumers in the US use and spend more on prescription drugs than any other country, making manufacturers central to meeting this demand and supporting public health. This role was evident during the COVID-19 pandemic, as brand name pharma producers researched, produced and distributed vital vaccines in record time. Aside from vaccine development, domestic manufacturers can attribute rising spending on brand name drugs to several factors, including an aging population, expanding health coverage, new drug approvals and medical advances in expensive specialty areas like rare diseases and oncology. Still, mounting scrutiny facing brand name pharma makers focuses on pricing policies and patent protections, suggesting that the industry’s strong performance indicates monopolistic practices and price hikes rather than rising prescription drug use. Operating pressures have weakened revenue growth, with revenue declining at a CAGR of 0.5% over the past five years to an estimated $271.2 billion, including expected growth of 3.0% in 2025.
Answer any industry question in minutes with our entire database at your fingertips.
Feed trusted, human-driven industry intelligence straight into your platform.
Streamline your workflow with IBISWorld’s intelligence built into your toolkit.
IBISWorld's research coverage on the Brand-Name Pharmaceutical Manufacturing industry in the United States includes market sizing, forecasting, data and analysis from 2015-2030. The most recent publication was released August 2025.
The Brand-Name Pharmaceutical Manufacturing industry in the United States operates under the NAICS industry code 32541a. Brand name pharmaceutical manufacturers develop, produce and market pharmaceutical drugs under their proprietary brand names. These manufacturers often hold patents or other intellectual property rights to their drugs, granting them sole exclusivity to produce, distribute and sell their drug for the entire life of the patent. Related terms covered in the Brand-Name Pharmaceutical Manufacturing industry in the United States include biologic, biosimilar, orphan drug, patent cliff, outsource, over-the-counter , blockbuster drug, evergreening and drug candidate .
Products and services covered in Brand-Name Pharmaceutical Manufacturing industry in the United States include Oncology, Immunology and Metabolic diseases.
Companies covered in the Brand-Name Pharmaceutical Manufacturing industry in the United States include Abbvie inc., Pfizer Inc. and Johnson & Johnson.
The Performance chapter covers detailed analysis, datasets, detailed current performance, sources of volatility and an outlook with forecasts for the Brand-Name Pharmaceutical Manufacturing industry in the United States.
Questions answered in this chapter include what's driving current industry performance, what influences industry volatility, how do successful businesses overcome volatility, what's driving the industry outlook. This analysis is supported with data and statistics on industry revenues, costs, profits, businesses and employees.
The Products and Markets chapter covers detailed product and service segmentation, analysis of major markets and international trade data for the for the Brand-Name Pharmaceutical Manufacturing industry in the United States.
Questions answered in this chapter include how are the industry's products and services performing, what are innovations in industry products and services, what products or services do successful businesses offer and what's influencing demand from the industry's markets. This includes data and statistics on industry revenues by product and service segmentation and major markets.
The Geographic Breakdown chapter covers detailed analysis and datasets on regional performance of the Brand-Name Pharmaceutical Manufacturing industry in the United States.
Questions answered in this chapter include where are industry businesses located and how do businesses use location to their advantage. This includes data and statistics on industry revenues by location.
The Competitive Forces chapter covers the concentration, barriers to entry and supplier and buyer profiles in the Brand-Name Pharmaceutical Manufacturing industry in the United States. This includes data and statistics on industry market share concentration, barriers to entry, substitute products and buyer & supplier power.
Questions answered in this chapter include what impacts the industry's market share concentration, how do successful businesses handle concentration, what challenges do potential industry entrants face, how can potential entrants overcome barriers to entry, what are substitutes for industry services, how do successful businesses compete with substitutes and what power do buyers and suppliers have over the industry and how do successful businesses manage buyer & supplier power.
The Companies chapter covers Key Takeaways, Market Share and Companies in the Brand-Name Pharmaceutical Manufacturing industry in the United States. This includes data and analysis on companies operating in the industry that hold a market share greater than 5%.
Questions answered in this chapter include what companies have a meaningful market share and how each company is performing.
The External Environment chapter covers Key Takeaways, External Drivers, Regulation & Policy and Assistance in the Brand-Name Pharmaceutical Manufacturing industry in the United States. This includes data and statistics on factors impacting industry revenue such as economic indicators, regulation, policy and assistance programs.
Questions answered in this chapter include what demographic and macroeconomic factors impact the industry, what regulations impact the industry, what assistance is available to this industry.
The Financial Benchmarks chapter covers Key Takeaways, Cost Structure, Financial Ratios, Valuation Multiples and Key Ratios in the Brand-Name Pharmaceutical Manufacturing industry in the United States. This includes financial data and statistics on industry performance including key cost inputs, profitability, key financial ratios and enterprise value multiples.
Questions answered in this chapter include what trends impact industry costs and how financial ratios have changed overtime.
The Industry Data chapter includes 10 years of historical data with 5 years of forecast data covering statistics like revenue, industry value add, establishments, enterprises, employment and wages in the Brand-Name Pharmaceutical Manufacturing industry in the United States.
More than 6,000 businesses use IBISWorld to shape local and global economies
We were able to supplement our reports with IBISWorld’s information from both a qualitative and quantitative standpoint. All of our reporting now features some level of IBISWorld integration.
IBISWorld delivers the crisp business knowledge we need to drive our business. Whether it be serving up our major clients, winning new business or educating on industry issues, IBISWorld brings real value.
IBISWorld has revolutionised business information — which has proved commercially invaluable to exporters, investors and public policy professionals in Australia and overseas.
When you’re able to speak to clients and be knowledgeable about what they do and the state that they operate in, they’re going to trust you a lot more.
The market size of the Brand-Name Pharmaceutical Manufacturing industry in the United States is $271.2bn in 2026.
There are 2,515 businesses in the Brand-Name Pharmaceutical Manufacturing industry in the United States, which has grown at a CAGR of 2.5 % between 2020 and 2025.
The Brand-Name Pharmaceutical Manufacturing industry in the United States is likely to be significantly impacted by import tariffs with imports accounting for a high share of industry revenue.
The Brand-Name Pharmaceutical Manufacturing industry in the United States is likely to be significantly impacted by export tariffs with exports accounting for a high share of industry revenue.
The market size of the Brand-Name Pharmaceutical Manufacturing industry in the United States has been declining at a CAGR of 0.5 % between 2020 and 2025.
Over the next five years, the Brand-Name Pharmaceutical Manufacturing industry in the United States is expected to grow.
The biggest companies operating in the Brand-Name Pharmaceutical Manufacturing industry in the United States are Abbvie inc., Pfizer Inc. and Johnson & Johnson
Pharmaceutical research and development and Manufacturing chemical pharmaceutical preparations are part of the Brand-Name Pharmaceutical Manufacturing industry in the United States.
The company holding the most market share in the Brand-Name Pharmaceutical Manufacturing industry in the United States is Abbvie inc..
The level of competition is high and increasing in the Brand-Name Pharmaceutical Manufacturing industry in the United States.